Talk:4-CA: Difference between revisions

>LockPicker
Removed auditory and visual effects panel
>LockPicker
m Several minor changes
Line 3: Line 3:
{{headerpanel|{{Approval}}}}
{{headerpanel|{{Approval}}}}
{{Warning/4-CA}}
{{Warning/4-CA}}
{{Distinguish|4-CMA|4-FA}}
{{Distinguish|4-CMA}}
{{SummarySheet}}
{{SummarySheet}}
{{SubstanceBox/4-CA}}
{{SubstanceBox/4-CA}}
Line 12: Line 12:


==History and culture==
==History and culture==
{{historyStub}}
 
In 1963, the effects of [[4-CMA]] were described by the Swiss researchers Pletscher, Burkard, Bruderer and Gey.<ref>{{cite journal|last1=Pletscher|first1=A.|last2=Burkard|first2=W.P.|last3=Bruderer|first3=H.|last4=Gey|first4=K.F.|date=1963|title=Decrease of cerebral 5-hydroxytryptamine and 5-hydroxyindolacetic acid by an arylalkylamine|journal=Life Sciences|volume=2|issue=11|pages=828-833|doi=10.1016/0024-3205(63)90094-8|issn=0024-3205}}</ref> Because of their results, several other chlorinated analogs of [[amphetamine]], including 4-CA had been synthesized by the American pharmaceutical company Eli Lilly and Company. They were evaluated as [[Appetite_suppression|appetite suppressants]].<ref name="Fuller1992">{{cite journal|last1=Fuller|first1=Ray W.|date=1992|title=Effects of ''p''-chloroamphetamine on brain serotonin neurons|journal=Neurochemical Research|volume=17|issue=5|pages=449–456|doi=10.1007/BF00969891|issn=1573-6903}}</ref><ref name="OwenJr1963>{{cite journal|last1=Owen Jr.|first1=John E.|date=1963|title=Psychopharmacological Studies of Some 1-(Chlorophenyl)-2-aminopropanes I: Effects on Appetitive-Controlled Behavior|journal=Journal of Pharmaceutical Sciences|volume=52|issue=7|pages=679-683|doi=10.1002/jps.2600520716|issn=0022-3549}}</ref> U.S. American biochemist Ray W. Fuller and collegues resynthesized these compounds and found that 4-CA was the most potent [[serotonin]] depletor.<ref>{{cite journal|last1=Fuller|first1=Ray W.|last2=Hines|first2=C.W.|last3=Mills|first3=J.|date=1965|title=Lowering of brain serotonin level by chloramphetamines|journal=Biochemical Pharmacology|volume=14|issue=4|pages=483-488|doi=10.1016/0006-2952(65)90221-2|issn=0006-2952}}</ref> Van Praag and others conducted comprehensive clinical study on humans in 1971, and it has been found to have a potent [[antidepressant]] effect.<ref>{{cite journal|last1=van Praag|first1=H.M.|last2=Schut|first2=T.|last3=Bosma|first3=E.|last4=van den Bergh|first4=R.|date=1971|title=A comparative study of the therapeutic effects of some 4-chlorinated amphetamine derivatives in depressive patients|journal=Psychopharmacologia|volume=20|issue=1|pages=66–76|doi=10.1007/BF00404060|issn=1432-2072}}</ref><ref name="Shulgin1978"></ref>  In  1972, Sanders-Bush, Bushing and Sulser from Vanderbilt University first described a decrease in tryptophane hydroxylase activity.<ref name="Shulgin1978">{{cite book|last=Shulgin|first=Alexander T.|editor1-last=Iversen|editor1-first=Leslie L.|editor2-last=Iversen|editor2-first=Susan D.|editor3-last=Snyder|editor3-first=Solomon H.|date=1978|title=Handbook of Psychopharmacology|volume=Volume 11: Stimulants|url=https://www.erowid.org/archive/rhodium/chemistry/shulgin.pea.sar.hop.html#35|chapter=Chapter 6 |location=New York|publisher=Plenum Press,|page=313 et seq.|isbn=978-1-4757-0512-6|author-link=Alexander Shulgin}}</ref><ref>{{cite journal|last1=Sanders-Bush|first1=E.|last2=Bushing|first2=J.A.|last3=Sulser|first3=F.|date=1972|title=p-Chloroamphetamine—inhibition of cerebral tryptophan hydroxylase|journal=Biochemical Pharmacology|volume=21|issue=10|pages=1501-1510|doi=10.1016/0006-2952(72)90375-9|issn=0006-2952}}</ref> 4-CA became a common tool for selective modification of the serotonergic function<ref name="Fuller1992"></ref> Yunger, McMaster, and Harvey described the related neurotoxicity in 1974.<ref name="Shulgin1978"></ref>  
In 1963, the effects of [[4-CMA]] were described by the Swiss researchers Pletscher, Burkard, Bruderer and Gey.<ref>{{cite journal|last1=Pletscher|first1=A.|last2=Burkard|first2=W.P.|last3=Bruderer|first3=H.|last4=Gey|first4=K.F.|date=1963|title=Decrease of cerebral 5-hydroxytryptamine and 5-hydroxyindolacetic acid by an arylalkylamine|journal=Life Sciences|volume=2|issue=11|pages=828-833|doi=10.1016/0024-3205(63)90094-8|issn=0024-3205}}</ref> Because of their results, several other chlorinated analogs of [[amphetamine]], including 4-CA had been synthesized by the American pharmaceutical company Eli Lilly and Company. They were examined as [[Appetite_suppression|appetite suppressants]].<ref name="Fuller1992">{{cite journal|last1=Fuller|first1=Ray W.|date=1992|title=Effects of ''p''-chloroamphetamine on brain serotonin neurons|journal=Neurochemical Research|volume=17|issue=5|pages=449–456|doi=10.1007/BF00969891|issn=1573-6903}}</ref><ref name="OwenJr1963>{{cite journal|last1=Owen Jr.|first1=John E.|date=1963|title=Psychopharmacological Studies of Some 1-(Chlorophenyl)-2-aminopropanes I: Effects on Appetitive-Controlled Behavior|journal=Journal of Pharmaceutical Sciences|volume=52|issue=7|pages=679-683|doi=10.1002/jps.2600520716|issn=0022-3549}}</ref> U.S. American biochemist Ray W. Fuller and collegues resynthesized these compounds and found that 4-CA was the most potent [[serotonin]] depletor.<ref>{{cite journal|last1=Fuller|first1=Ray W.|last2=Hines|first2=C.W.|last3=Mills|first3=J.|date=1965|title=Lowering of brain serotonin level by chloramphetamines|journal=Biochemical Pharmacology|volume=14|issue=4|pages=483-488|doi=10.1016/0006-2952(65)90221-2|issn=0006-2952}}</ref> Van Praag and others conducted comprehensive clinical study on humans in 1971, and it has been found to have a potent [[antidepressant]] effect.<ref>{{cite journal|last1=van Praag|first1=H.M.|last2=Schut|first2=T.|last3=Bosma|first3=E.|last4=van den Bergh|first4=R.|date=1971|title=A comparative study of the therapeutic effects of some 4-chlorinated amphetamine derivatives in depressive patients|journal=Psychopharmacologia|volume=20|issue=1|pages=66–76|doi=10.1007/BF00404060|issn=1432-2072}}</ref><ref name="Shulgin1978"></ref>  4-CA became a common tool for selective modification of the serotonergic function<ref name="Fuller1992"></ref> Yunger, McMaster, and Harvey described the related neurotoxicity in 1974.<ref name="Shulgin1978">{{cite book|last=Shulgin|first=Alexander T.|editor1-last=Iversen|editor1-first=Leslie L.|editor2-last=Iversen|editor2-first=Susan D.|editor3-last=Snyder|editor3-first=Solomon H.|date=1978|title=Handbook of Psychopharmacology|volume=Volume 11: Stimulants|url=https://www.erowid.org/archive/rhodium/chemistry/shulgin.pea.sar.hop.html#35|chapter=Chapter 6 |location=New York|publisher=Plenum Press,|page=313 et seq.|isbn=978-1-4757-0512-6|author-link=Alexander Shulgin}}</ref>


==Chemistry==
==Chemistry==
4-Chloroamphetamine is a synthetic compound of the [[substituted amphetamine]] class. Amphetamines contain a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα. Amphetamines are alpha-methylated [[phenethylamines]]. 4-CA contains a chlorine atom at R4 of its phenyl ring and is a chlorinated analogue of [[amphetamine]].  
 
4-Chloroamphetamine is a synthetic compound of the [[substituted amphetamine]] class. Amphetamines contain a [[phenethylamine]] core featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα. Amphetamines are alpha-methylated [[phenethylamines]]. 4-CA contains a chlorine atom at R4 of its phenyl ring and is a chlorinated analogue of [[amphetamine]].  
==Pharmacology==
==Pharmacology==
{{pharmacology}}
{{pharmacology}}
4-Chloroamphetamine acts as a selective [[releasing agent]] of the [[Monoamine_neurotransmitters|monoamine neurotransmitter]] [[serotonin]]. At higher doses, it can deplete brain serotonin.<ref name="Fuller1992"/>
A decreases in tryptophane hydroxylase activity could be observed.<ref>{{cite journal|last1=Sanders-Bush|first1=E.|last2=Bushing|first2=J.A.|last3=Sulser|first3=F.|date=1972|title=p-Chloroamphetamine—inhibition of cerebral tryptophan hydroxylase|journal=Biochemical Pharmacology|volume=21|issue=10|pages=1501-1510|doi=10.1016/0006-2952(72)90375-9|issn=0006-2952}}</ref>


==Subjective effects==
==Subjective effects==
Line 51: Line 55:
*'''[[Effect::Temporary erectile dysfunction]]'''
*'''[[Effect::Temporary erectile dysfunction]]'''
*'''[[Effect::Vibrating vision]]'''
*'''[[Effect::Vibrating vision]]'''


}}
}}
Line 91: Line 89:
There are currently {{#ask:[[Category:SUBSTANCE]][[Category:Experience]] | format=count}} experience reports which describe the effects of this substance in our [[experience index]].
There are currently {{#ask:[[Category:SUBSTANCE]][[Category:Experience]] | format=count}} experience reports which describe the effects of this substance in our [[experience index]].
{{#ask: [[Category:SUBSTANCE]][[Category:Experience]]|format=ul|Columns=1}}
{{#ask: [[Category:SUBSTANCE]][[Category:Experience]]|format=ul|Columns=1}}
Additional experience reports can be found here:
* [https://www.erowid.org/experiences/subs/exp_SUBSTANCE.shtml Erowid Experience Vaults: SUBSTANCE] <!-- Check the link to see if it exists -->


==Toxicity and harm potential==
==Toxicity and harm potential==
{{toxicity}}
{{toxicity}}
It is strongly recommended that one use [[responsible use|harm reduction practices]] when using this substance.
It is strongly recommended that one use [[responsible use|harm reduction practices]] when using this substance.
===Lethal dosage===
 
===Tolerance and addiction potential===
===Tolerance and addiction potential===
===Dangerous interactions===
===Dangerous interactions===
Return to "4-CA" page.